• Regulatory

ABPI BIA responses MHRA consultation EU Exit no deal contingency legislation

The ABPI and BIA have worked together to develop this joint submission to the MHRA consultation. We have provided our members’ views on how the MHRA’s legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period. This consultation covers no-deal proposals on medicines, clinical trials and medical devices.

Influencing and shaping our sector, BIA update: July - October 2018

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from July to October 2018.

BIA MHRA Conference Report 2018.pdf

The UK BioIndustry Association (BIA) and the Medicines and Healthcare products Regulatory Agency (MHRA) brought together experts from across the life sciences sector to discuss some hot topics and important developments through a series of presentations and panel discussions.